TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15894837

Group type: EXPERIMENTAL
Intervention: Combination therapy (temocapril 1 mg + losartan 12.5 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Temocapril 1 mg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Losartan 12.5 mg
Number of subjects: 31
Study: 11379375

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 9407446

Group type: EXPERIMENTAL
Intervention: Diabetic nephropathy in IDDM patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 8506890

Group type: EXPERIMENTAL
Intervention: Standardized garlic powder tablets (300 mg three times a day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 3554055

Group type: EXPERIMENTAL
Intervention: Electronic fetal heart rate monitoring
Number of subjects: 246

Group type: COMPARATOR
Intervention: Auscultation
Number of subjects: 246
Study: 29536106

Group type: EXPERIMENTAL
Intervention: Fine Structure Processing (FSP) strategy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: FS4 strategy (low stimulation rate)
Number of subjects: 26

Group type: COMPARATOR
Intervention: FS4 strategy (high stimulation rate)
Number of subjects: 26
Study: 26442648

Group type: EXPERIMENTAL
Intervention: ABO-D matched RBC transfusions
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Extended matched RBC transfusions
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Per-protocol analysis
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Post hoc analysis of patients receiving RBCs without PLT transfusions
Number of subjects: 853
Study: 24286115

Group type: EXPERIMENTAL
Intervention: Insulin aspart administered by InsuJet
Number of subjects: 10

Group type: COMPARATOR
Intervention: Insulin aspart administered by FlexPen
Number of subjects: 10
Study: 23037329

Group type: EXPERIMENTAL
Intervention: Silk-like fabric linens
Number of subjects: 582

Group type: COMPARATOR
Intervention: Standard hospital linens
Number of subjects: 582
Study: 19915206

Group type: EXPERIMENTAL
Intervention: Multifaceted minimal-lift environment (engineering, administrative, and behavioral controls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Engineering controls only (comparison nursing unit)
Number of subjects: 0
Study: 18695272

Group type: EXPERIMENTAL
Intervention: Oral salbutamol (0.1 mg/kg/dose) three times a day for 7 days
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo three times a day for 7 days
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Oral salbutamol (0.1 mg/kg/dose)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 15920045

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 12127929

Group type: EXPERIMENTAL
Intervention: Ala‐Gln group received 0.972 g amino acids/kg/day and 0.417 g of L‐alanyl‐L‐glutamine (Ala‐Gln)/kg/day.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (Conv) received 1.5 g amino acids/kg/day.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ala‐Gln group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conv group
Number of subjects: 48
Study: 10219027

Group type: EXPERIMENTAL
Intervention: Phacoemulsification or trabeculectomy with shield on non-operated eye
Number of subjects: 60
Study: 7781634

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia with IPPV (n = 71)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Halothane anaesthesia with spontaneous breathing (n = 66)
Number of subjects: 137
Study: 1697824

Group type: EXPERIMENTAL
Intervention: Low-dose heparin administration
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group (no anticoagulants)
Number of subjects: 103
Study: 668268

Group type: EXPERIMENTAL
Intervention: 30 ml of aqueous ethanol diluted to 25% administered orally
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (15 subjects)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Blood alcohol concentration
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Gradient of the blood alcohol curve
Number of subjects: 31
Study: 30590412

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)-based therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Protease inhibitor (PI/r)-based therapy
Number of subjects: 42
Study: 26659070

Group type: EXPERIMENTAL
Intervention: Moderate fat (40 E%) with 20 E% MUFA and low in glycemic index (MUFA)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Low fat (25 E%) and medium in glycemic index (LF)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control (35 E% fat) and high in glycemic index (CTR)
Number of subjects: 131
Study: 26476332

Group type: EXPERIMENTAL
Intervention: iTBS over the prefrontal cortex
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 41
Study: 23375512

Group type: EXPERIMENTAL
Intervention: Single 24-hour pain intensity recall rating
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite scores made up of 2 to 9 different ratings
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite scores made up of 1 to 9 24-hour pain intensity recall ratings
Number of subjects: 0
Study: 20122814

Group type: EXPERIMENTAL
Intervention: Brown diet (rich in Maillard reaction products)
Number of subjects: 20

Group type: COMPARATOR
Intervention: White diet (poor in Maillard reaction products)
Number of subjects: 20
Study: 19829702

Group type: EXPERIMENTAL
Intervention: Comprehensive nursing and physiotherapy assessment, individually tailored exercise strategies, nurse home visits, and telephone follow-up for 24 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care condition (control group).
Number of subjects: 0
Study: 16709215

Group type: EXPERIMENTAL
Intervention: Toremifene 20 mg daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 15645890

Group type: EXPERIMENTAL
Intervention: 14% hydrogen-peroxide whitening strip
Number of subjects: 17

Group type: COMPARATOR
Intervention: 6.5% hydrogen-peroxide whitening strip (positive control)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both strips
Number of subjects: 17
Study: 11706099

Group type: EXPERIMENTAL
Intervention: 9 mg IA r‐proUK over 120 minutes plus IV fixed‐dose heparin
Number of subjects: 180

Group type: COMPARATOR
Intervention: IV fixed‐dose heparin alone
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: r‐proUK treatment
Number of subjects: 180
Study: 9681371

Group type: EXPERIMENTAL
Intervention: Pemoline 10 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pemoline 20 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pemoline 30 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pemoline 40 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8027415

Group type: EXPERIMENTAL
Intervention: 10 mg/day haloperidol
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 30 mg/day haloperidol
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 80 mg/day haloperidol
Number of subjects: 55
Study: 2553993

Group type: EXPERIMENTAL
Intervention: Chemotherapy with IFN-beta and IFN-gamma
Number of subjects: 37

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 37
Study: 1106935

Group type: EXPERIMENTAL
Intervention: Digoxin solution in capsule form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digoxin tablets with 97% dissolution rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digoxin formulations
Number of subjects: 0
Study: 31601111

Group type: EXPERIMENTAL
Intervention: SBML
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 80
Study: 30543665

Group type: EXPERIMENTAL
Intervention: Auditory stimulation embedded in music
Number of subjects: 18

Group type: COMPARATOR
Intervention: Music alone (sham, control)
Number of subjects: 18
Study: 27595956

Group type: EXPERIMENTAL
Intervention: 1 ml 2% lidocaine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2 ml 1% lidocaine
Number of subjects: 36
Study: 24355668

Group type: EXPERIMENTAL
Intervention: Daily self-weighing intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Delayed-intervention control group
Number of subjects: 91
Study: 22173280

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg co-administered with gemfibrozil 600 mg
Number of subjects: 12
Study: 20848164

Group type: EXPERIMENTAL
Intervention: midazolam (0.04 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: droperidol (0.1 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: saline
Number of subjects: 120
Study: 17851194

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NICE appraisal of cholinesterase inhibitors
Number of subjects: 0
Study: 16240563

Group type: EXPERIMENTAL
Intervention: Alcohol (six 12-oz cans of beer)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (juice)
Number of subjects: 10
Study: 12456899

Group type: EXPERIMENTAL
Intervention: Glucose 30% orally and placebo (Unguentum Merck) on the skin
Number of subjects: 201

Group type: COMPARATOR
Intervention: EMLA on the skin and orally administered placebo (sterile water)
Number of subjects: 201
Study: 10525592

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg cisatracurium (3x ED(95))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg cisatracurium (2x ED(95))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg atracurium (2x ED(95))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All three groups (0.1 mg/kg cisatracurium, 0.15 mg/kg cisatracurium, 0.5 mg/kg atracurium)
Number of subjects: 45
Study: 7793585

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 30
Study: 1775892

Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 7018179

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 5 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pindolol 1.0 mg i.v.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of ISDN and pindolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6656169

Group type: EXPERIMENTAL
Intervention: 3100 NOON-Units (NU) with 3 injections in group A
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 9100 NOON-Units (NU) with 6 injections in group B
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 28
Study: 30370956

Group type: EXPERIMENTAL
Intervention: Carboplatin-topotecan (CT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Alvocidib, cytarabine, and mitoxantrone (FLAM)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sirolimus combined with mitoxantrone, etoposide, and cytarabine (S-MEC)
Number of subjects: 90
Study: 30071980

Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme (n = 88)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Treatment as usual (n = 76)
Number of subjects: 164
Study: 27091540

Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24474647

Group type: EXPERIMENTAL
Intervention: 9-beam lasercomb treatment in female subjects
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 12-beam lasercomb treatment in female subjects
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 7-beam lasercomb treatment in male subjects
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 9-beam lasercomb treatment in male subjects
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: 12-beam lasercomb treatment in male subjects
Number of subjects: 269

Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 269
Study: 22761115

Group type: EXPERIMENTAL
Intervention: Sealed CO(2) insufflation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open CO(2) insufflation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Sealed and Open CO(2) insufflation)
Number of subjects: 60
Study: 20047816

Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale (FSS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Physical Self‐Maintenance Scale (PSMS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Handwriting performance (measured by ComPET)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: FSS, specific PSMS items, and handwriting measures
Number of subjects: 50
Study: 17484373

Group type: COMPARATOR
Intervention: Lactulose 0 g (placebo)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lactulose 2 g (low-dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lactulose 4 g (high-dose)
Number of subjects: 24
Study: 16286541

Group type: COMPARATOR
Intervention: 1 g/kg of IVIG on day 1 and placebo on day 2 (group 1)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: 1 g/kg of IVIG on 2 consecutive days (group 2)
Number of subjects: 173
Study: 12515573

Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 100

Group type: COMPARATOR
Intervention: Levodopa plus benserazide
Number of subjects: 100
Study: 10588559

Group type: EXPERIMENTAL
Intervention: 10 mL 1% lidocaine with epinephrine 1:200,000
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 mL 1% lidocaine without epinephrine
Number of subjects: 20
Study: 8961492

Group type: EXPERIMENTAL
Intervention: Buprenorphine sublingually
Number of subjects: 52

Group type: COMPARATOR
Intervention: Morphine via patient-controlled analgesia system
Number of subjects: 52
Study: 1762067

Group type: EXPERIMENTAL
Intervention: R-ibuprofen (600 mg) plus S-[aromatic-2H4]ibuprofen (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: S-ibuprofen (600 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen (800 mg) plus S-[aromatic-2H4]ibuprofen (10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Racemic ibuprofen
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: S-ibuprofen
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Carboxyibuprofen
Number of subjects: 8
Study: 7044098

Group type: EXPERIMENTAL
Intervention: Cisplatin 120 mg/m2
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cisplatin 60 mg/m2
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2 to 120 mg/m2 crossover
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Cisplatin 60 mg/m2 and 120 mg/m2
Number of subjects: 37
Study: 31589177

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vitamin D status
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Gut microbiome influence
Number of subjects: 10
Study: 29017158

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) 2,700 mg/day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (900 mg of edible paraffin)
Number of subjects: 44
Study: 26445224

Group type: EXPERIMENTAL
Intervention: Booklet only
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Booklet plus nurse support (up to four 30-minute sessions)
Number of subjects: 186
Study: 23414234

Group type: EXPERIMENTAL
Intervention: Assertive Outreach (AO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 22072466

Group type: COMPARATOR
Intervention: Conventional injection technique (CI)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proximal phalanx injection technique (P1I)
Number of subjects: 40
Study: 19336509

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) - 50,000 IU weekly
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ergocalciferol (D2) - 50,000 IU weekly
Number of subjects: 30

Group type: COMPARATOR
Intervention: UV light therapy - exposed skin to UV light five times a week
Number of subjects: 30
Study: 17719312

Group type: EXPERIMENTAL
Intervention: Perindopril (2 to 4 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 15013936

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 4937

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4937
Study: 15299053

Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG myocardial scintigraphy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control subjects (n=11; 11 men; mean age 37.6 ± 9.3 years)
Number of subjects: 9
Study: 10361264

Group type: EXPERIMENTAL
Intervention: Griseofulvin plus oral prednisolone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Griseofulvin alone
Number of subjects: 30
Study: 8528724

Group type: EXPERIMENTAL
Intervention: Health risk appraisal (HRA) activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1773708

Group type: EXPERIMENTAL
Intervention: Mixtard
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Actraphane
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Humulin M3
Number of subjects: 7

Group type: COMPARATOR
Intervention: NPH insulin alone
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Syringe mixed regular and NPH insulin
Number of subjects: 7
Study: 7333003

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol given 10 min before exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol given 1 hr before exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metaproterenol tablets given 1 hr before exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Metaproterenol tablets given 2 hr before exercise
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31413896

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A treatment
Number of subjects: 50
Study: 30006297

Group type: EXPERIMENTAL
Intervention: High Vitamin D
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Low n-3PUFA
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency ([25(OH)D] < 20 ng/ml)
Number of subjects: 732
Study: 27858079

Group type: EXPERIMENTAL
Intervention: bFGF 35000IU + normal saline 20 mL, compression inhalation, day 1, every 20min, continued for 3 d
Number of subjects: 40

Group type: COMPARATOR
Intervention: normal saline 5 mL + dexamethasone 5 mg + gentamicin 80000 U + chymotrypsin 4000 U, compression inhalation, twice a day, every 20 min, continued for 3 d
Number of subjects: 40
Study: 25070547

Group type: COMPARATOR
Intervention: Continuous cycling (CC) using 20 mcg ethinyl estradiol/100 mcg levonorgestrel with no hormone-free interval
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Increased dose (ID) using 30 mcg ethinyl estradiol/150 mcg levonorgestrel cyclically
Number of subjects: 31
Study: 22883337

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 20564362

Group type: EXPERIMENTAL
Intervention: Reconciliation workshop with PTSD psychoeducation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reconciliation workshop without PTSD psychoeducation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 18490196

Group type: EXPERIMENTAL
Intervention: CSE 900 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15666173

Group type: EXPERIMENTAL
Intervention: Milk thistle (450 mg extract capsules t.i.d. from day 2 to day 30)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (no plant extract)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Meta-analysis of milk thistle-indinavir trials
Number of subjects: 16
Study: 12618646

Group type: EXPERIMENTAL
Intervention: Test Request Form (TRF)
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Memorandum Pocket Card (MPC)
Number of subjects: 1412

Group type: EXPERIMENTAL
Intervention: Dual intervention group (TRF + MPC)
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1412
Study: 10204754

Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8805965

Group type: EXPERIMENTAL
Intervention: Thermal biofeedback (TBF) training for hand (7 sessions) and foot (9 sessions) warming
Number of subjects: 42

Group type: COMPARATOR
Intervention: Monitoring BPs at home (control group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Thermal biofeedback (TBF) training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intensive follow-up emphasizing regular home practice with an electronic TBF device
Number of subjects: 42

Group type: COMPARATOR
Intervention: Regular follow-up (visits every 3 months)
Number of subjects: 42
Study: 1625204

Group type: EXPERIMENTAL
Intervention: Cocaine (0, 12.5, 25 and 50 mg, i.v.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bromocriptine (0, 1.2 and 2.5 mg given orally 2 hr before the cocaine injection)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cocaine + Bromocriptine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bromocriptine alone
Number of subjects: 8
Study: 6435446

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 30421335

Group type: EXPERIMENTAL
Intervention: On-meals (home delivery of 10 meals/week for 12 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Off-meals (12 weeks usual care and a Choose MyPlate healthy eating brochure)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: On-meals
Number of subjects: 44
Study: 28334273

Group type: EXPERIMENTAL
Intervention: Mendelian randomization-based pathway enrichment analysis (MRPEA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional pathway association analysis (TPAA)
Number of subjects: 0
Study: 26940371

Group type: EXPERIMENTAL
Intervention: (+)‐delmopinol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (‐)‐delmopinol
Number of subjects: 0

Group type: COMPARATOR
Intervention: (±)‐delmopinol (racemate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three test solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (+)‐delmopinol and (‐)‐delmopinol
Number of subjects: 0
Study: 24335542

Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy with Solitaire stent
Number of subjects: 25